Abstract: Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, provided herein are therapeutic PAs comprising a PA backbone and a therapeutic agent. In some embodiments, the peptide amphiphiles are co-assembled into nanofibers. In some embodiments, the nanofibers may be used for the treatment of atherosclerosis or related disease.

Abstract: A machine learning attack resistant strong PUF with a dual-edge sampling function comprises switch units, a first arbiter and a second arbiter. The first arbiter is for determining a sequential order of delays at a rising edge of signals input to a first input terminal and a second input terminal of the first arbiter. The second arbiter is for determining a sequential order of delays at a falling edge of signals input to a first input terminal and a second input terminal of the second arbiter. Each switch unit is composed of eight MOS transistors. The strong PUF has a high capacity to resist machine learning attacks and small hardware expenditure through simple structural design of the switch units, realizing machine learning attack resistance and small hardware expenditure at the same time, and generating a large number of challenge response pairs through dual-edge sampling realized by the two arbiters.

Abstract: Methods and devices for detecting chiral properties from a sample are provided. Light may be directed towards a sample in contact with a chiral nanoparticle. Third harmonic Mie scattering (THMS) optical activity generated by the chiral nanoparticle in contact with the sample can then be detected. A device for detecting chiral properties of a sample is also contemplated that includes Nat least one microwell having a volume of ?about 1 microliter configured to hold a chiral nanoparticle capable of generating third harmonic Mie scattering (THMS) optical activity and a sample to be analyzed. The device includes a source of light configured to generate and direct light toward the at least one microwell containing the chiral nanoparticle and the sample and at least one detector configured to detect third harmonic Mie scattering (THMS) generated by the chiral nanoparticle in the microwell.

Abstract: The present invention relates to a layered semi-parallel LDPC decoder system having a single permutation network, and belongs to the field of decoder hardware design. The system comprises a layered decoding architecture of the single permutation network, a layered semi-parallel decoding architecture of the single permutation network, a pipeline design for layered semi-parallel decoding and a hardware framework of a layered semi-parallel LDPC decoder. The present invention removes a permutation network module between a check node and a variable node by modifying the cyclic shift value of each information block transferred from the variable node to the check node, i.e., the cyclic shift operation of the decoder can be completed through the single permutation network so as to reduce hardware resources of the decoder. A semi-parallel decoding structure is adopted, and meanwhile, a pipeline is added between half layers.

Abstract: This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new dermal adipocytes (DAs). Methods described herein comprise (a) grafting of human hair follicles or (b) direct delivery of conditioned media from in vitro cultured hair follicles, or (c) delivery of purified individual factors secreted by hair follicles, or (d) delivery of small molecule agonists that mimic hair derived signaling activities, or (e) delivery of small molecule antagonists that inhibit anti-adipogenic programs, or (f) delivery of small molecule agonists of pro-adipogenic programs to convert endogenous wound or scar skin fibroblasts into new DAs.

Abstract: Methods and systems for delivery of pulsated air to a user using a device including a flow generator to generate a continuous air flow, a first actuator comprising a pulsated flow delivery mechanism configured to generate a pulsated air flow from the continuous air flow based on a pre-determined duty cycle to vary a frequency of the pulsated air flow, a user interface configured to generate and deliver vortices of pulsated air to the user at the frequency of the pulsated air flow, and a set of tubing to couple the flow generator, the first actuator, and the user interface.

Abstract: A structure for changing the attitude of a spacecraft is provided including an elongated member and a plurality of actuators coupled to the elongated member. The elongated member is coupled to the spacecraft. The elongated member has a length and an angular position relative to an axis. The plurality of actuators are configured to deflect the angular position of the elongated member relative to the axis and to alter the length of the elongated member.

Abstract: The current methods and compositions provide for a novel therapeutic method for treating patients diagnosed with melanoma, especially those that have become resistant to certain other therapies. Accordingly, certain aspects of the disclosure relate to a method for treating melanoma in a subject, the method comprising administering a composition comprising a ferroptosis-inducing agent or other dedifferentiated melanoma-targeting agent to the subject.

Abstract: A system and method for beam management in a wireless network are provided. A learning module having a trained classification module processes received I/Q input samples to determine transmitted beam information of incoming RF transmissions. The learning module includes a beam inference engine to determine waveforms waveform characteristics of incoming RF transmissions beams, and an angle of arrival engine operative to determine an angle of arrival of the incoming RF transmissions beams on an antenna array. An incoming RF transmission beam and angle of arrival are selected based on the determined waveforms for beam management operations.

Abstract: In response to a detected presence of an intended target appliance within a logical topography of controllable appliances identity information associated with the intended target appliance is used to automatically add to a graphical user interface of a controlling device an icon representative of the intended target appliance and to create at a Universal Control Engine a listing of communication methods for use in controlling corresponding functional operations of the intended target appliance. When the icon is later activated, the controlling device is placed into an operating state appropriate for controlling functional operations of the intended target appliance while the Universal Control Engine uses at least one of the communication methods to transmit at least one command to place the intended target appliance into a predetermined operating state.

Abstract: The present invention relates to a customized stretchable wearable device and a manufacturing method therefor, enabling the manufacturing of a customized stretchable wearable device which fits the body characteristics of a wearing subject who is wearing the wearable device, thereby enabling good wear comfort and sense of operation, and also a beautiful exterior.

Abstract: Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.

Abstract: An interactive Pepper's Ghost system includes a sensor configured to detect a parameter indicative of an orientation of a handheld device. The Pepper's Ghost system also includes a controller configured to receive, from the sensor, sensor feedback corresponding to the parameter indicative of the orientation of the handheld device. The controller is configured to control a Pepper's Ghost visual effect based on the sensor feedback.

Abstract: The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.

Abstract: A semiconductor chip for correcting an aligned error comprises a memory array is provided. The semiconductor chip includes a transceiver circuit and an Error Correction Code (ECC) circuit. The ECC circuit is configured to receive target data to be encoded, encode the target data by multiplying a generator matrix of a previously generated ECC by the target data, store the encoded target data in the memory array, check a data transformed from the encoded target data, and generate an error corrected data by correcting only a single error of the transformed data and an adjacent error that does not exceed a first value boundary of a predetermined number of bits by using a parity check matrix of the ECC, and output the error corrected data.

Abstract: The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.

Abstract: The invention includes compositions comprising a chimeric antigen receptor (CAR) specific for an GD T Cell receptor (anti-GD TCR CAR), vectors comprising the same, compositions comprising anti-GD TCR CAR vectors packaged in viral particles, and recombinant T cells or other effector cells comprising the anti-GD TCR CAR of the invention. The invention also includes methods of making a genetically modified T cell expressing an anti-GD TCR CAR wherein the expressed CAR comprises an extracellular domain that binds to GD T cells or to cells expressing a GD TCR.

Abstract: The present invention relates to organic thin film sensors and the preparation and use thereof in sensing applications, and in particular in glucose sensing. The sensor is characterised by a layered structure comprising a porous wicking layer whose surface is configured to receive a liquid sample. An enzyme is disposed on or within the porous layer for facilitating the generation of a charge carrier from an analyte. A polymer layer in contact with the porous layer is connected to an ohmic conductor for applying a gate voltage to the polymer layer, the polymer layer being conductive to the charge carrier; and an organic semiconducting layer is connected to a source electrode and a drain electrode.

Abstract: A quantum charge-coupled device including a first ion, a second ion, a fixed ion trap, an adjustable ion trap, and an excitation light source is provided. The fixed ion trap is configured to stationarily trap the first ion. The adjustable ion trap works as an ion rail disposed beside the fixed ion trap, wherein the ion rail is configured to make the second ion move at a constant velocity along the ion rail. The excitation light source is configured to irradiate an incident light beam. The incident light beam includes a series of light pulses and covers the first ion and the second ion when a distance between them becomes less than or equal to a proximity range, such that a quantum entangled state is directly built between the first ion and the second ion in uniform motion.

Abstract: The present invention includes compositions and methods of for treating plants infected with fungal pathogens by contacting an infected plant or plant at risk of infection with a fungicidal composition comprising an fungicide selected from copper compound such as copper octanoate or copper hydroxide, or a triazole fungicide such as myclobutanil, propionazole, tebuconazole or epoxiconazole, an enhancer selected from apyrase inhibitors, e.g., N-(m-tolyl)-[1,1?-biphenyl]-4-sulfonamide, S-heptyl 2-oxo-2H-chromene 3-carbothioate, 3-(N-(4-bromophenyl) sulfamoyl)-N-(3-nitrophenyl)benzamide, or (E)-3-methyl-N-(1-(naphthalen-2-yl) ethylidene)benzohydrazide and, optionally, a phytologically-acceptable inert carrier.